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Abstract:  Multidrug  resistance  is  a  phenomenon  whereby  tumors  become  resistant  to 
structurally unrelated anticancer drugs. P-glycoprotein belongs to the large ATP-binding 
cassette  (ABC)  transporter  superfamily  of  membrane  transport  proteins.  P-glycoprotein 
mediates  resistance  to  various  classes  of  anticancer  drugs  including  vinblastine, 
daunorubicin, and paclitaxel, by actively extruding the drugs from the cells. The quest for 
inhibitors  of  anticancer  drug  efflux  transporters  has  uncovered  natural  compounds, 
including  (-)-epigallocatechin  gallate,  curcumin,  capsaicin,  and  guggulsterone,  as 
promising  candidates.  In  this  review,  studies  on  the  effects  of  natural  compounds  on  
P-glycoprotein and anticancer drug efflux transporters are summarized. 
Keywords:  P-glycoprotein;  ABC  transporter;  anticancer  drug;  multidrug  resistance; 
phytochemical; cancer chemoprevention 
 
1. Introduction 
Cancer is the leading cause of death in Japan, and the second cause of death in the United States. 
Carcinogenesis is generally recognized as a multistep process in which a normal cell acquires specific 
phenotypic characteristics including self-sufficiency in growth signals, evasion of apoptosis, limitless 
replicative  potential,  sustained  angiogenesis  and  the  ability  to  undergo  tissue  invasion  and  
metastasis [1]. 
Cancer chemotherapy is the treatment of cancer using anticancer drugs with the aim to achieve and 
maintain  remission.  Multidrug  resistance  is  a  phenomenon  of  resistance  of  tumors  to  chemically 
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unrelated  anticancer  drugs,  and  is  one  of  the  most  formidable  challenges  in  the  field  of  cancer 
chemotherapy.  Multidrug  resistance  can  have  many  causes,  but  the  most  commonly  encountered 
mechanism  in  the  laboratory  is  the  increased  efflux  of  cytotoxic  drugs  by  energy-dependent 
transporters. P-glycoprotein belongs to the large ATP-binding cassette (ABC) transporter superfamily 
of  membrane  transport  proteins,  and  was  the  first  member  to  be  identified  [2–4].  P-glycoprotein 
mediates resistance to a variety of pharmacologically unrelated anticancer drugs, such as vinblastine, 
vincristine, daunorubicin, epirubicin, etoposide, imatinib, irinotecan, and paclitaxel [2–4]. 
Cancer prevention is aimed to reduce the cancer mortality by reduction in the incidence of the 
carcinogenic  process  [5–7].  Fruits  and  vegetables  are  excellent  sources  of  fiber,  vitamins,  and 
minerals, but they also contain various phytochemicals that may provide substantial health benefits 
beyond basic nutrition [5–7]. Phytochemicals are non-nutritive components in the plant-based diet that 
possess substantial anticarcinogenic properties. (-)-Epigallocatechin gallate, curcumin, and capsaicin 
serve  as  a  wide  variety  of  naturally  occurring  phytochemicals  with  cancer  chemopreventive  
activity [5–7]. 
Recently,  several  studies  have  documented  the  ability  of  chemopreventive  phytochemicals  to 
increase the sensitivity of cancer cells to anticancer drugs. Natural compounds including flavonoids 
such as quercetin, morin, and (-)-epigallocatechin gallate, curcumin, capsaicin, and [6]-gingerol can 
reverse the multidrug resistance by the inhibition of anticancer drug efflux transporter P-glycoprotein 
and other ABC transporters [8–11]. In this review, studies on the effects of natural compounds on 
ABC transporters are summarized, for the future development of safe and effective inhibitors of ABC 
transporters to overcome multidrug resistance in human cancer. 
2. Multidrug Resistance and Cancer Chemoprevention 
2.1. P-glycoprotein 
P-glycoprotein is encoded by MDR1, also referred to as ABCB1 [2–4]. The human MDR1 (ABCB1) 
gene  is  located  on  chromosome  7q21.  It  consists  of  28  exons,  which  encode  a  1280-amino  acid 
glycoprotein. The molecular structure of P-glycoprotein consists of two bundles of six transmembrane 
helices that form a drug-binding cavity with two ATP-binding sites [2–4]. 
Besides  anticancer  agents,  various  clinically  important  drugs,  including  digoxin,  verapamil, 
cyclosporin A, tacrolimus, quinidine, talinolol, erythromycin, ivermectin, fexofenadine, progesterone 
and saquinavir, are substrates of P-glycoprotein [2–4]. P-glycoprotein is also expressed in normal 
tissues. It is abundant in the apical membranes of many pharmacologically important epithelial barriers, 
such as the intestinal epithelium, renal proximal tubular epithelium and the blood-brain barrier [2–4]. 
Therefore, it is considered that P-glycoprotein plays very important roles in the absorption, distribution 
and elimination of many commonly used drugs, and thus determines the efficacy and toxicity of drugs. 
For instance, P-glycoprotein at the apical membrane of enterocytes acts as a biochemical barrier and 
restricts the absorption of orally administered drugs. 
Recently,  pharmacotherapy  has  become  more  diversified  and  complex,  and  clinical  practice 
frequently  involves  the  concomitant  use  of  multiple  medications.  As  a  consequence,  drug-drug 
interactions are more likely to occur. The modulation of P-glycoprotein activity by a P-glycoprotein 
inhibitor  can  be  an  important  factor  in  modifying  the  bioavailability  and  tissue  distribution  of  Toxins 2010, 2    
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P-glycoprotein substrates. Many clinically significant P-glycoprotein-mediated drug-drug interactions 
have been reported [12]. 
In addition to drug-drug interactions, food-drug interactions can also occur. It is now established 
that  foods  can  have  pronounced  impacts  on  drug  absorption,  disposition  and  elimination  [13,14]. 
Grapefruit juice and the mild antidepressant St. John's wort (Hypericum perforatum) is a well known 
example of food-drug interactions [13,14]. 
2.2. Chemopreventive phytochemicals 
Epidemiological and experimental studies have highlighted the ability of micronutrients in fruits 
and vegetables to reduce the risk of cancer [5–7]. Recently, attention has focused on phytochemicals, 
non-nutritive components of a plant-based diet that possess cancer preventive properties [5–7]. 
The signaling pathways that govern cell proliferation, survival and oncogenesis are of prime interest 
in the biology of cancer. The nuclear factor B (NF-B) transcription factors (p50/p105 (NF-B1), 
p52/p100 (NF-B2), RelA (p65), RelB, c-Rel) and the pathways that control NF-B activation are best 
known  for  their  role  in  inflammatory  responses,  but  also  critical  to  many  physiological  and 
pathophysiological responses, including cell differentiation, adhesion, survival, and apoptosis [15,16]. 
In most resting cells, NF-B is sequestered in the cytoplasm by binding to the inhibitory IB proteins. 
NF-B is activated by a variety of stimuli such as carcinogens, inflammatory agents including phorbol 
esters, bacterial endotoxins, and tumor necrosis factor (TNF). These stimuli promote dissociation of 
IB  through  phosphorylation,  ubiquitination  and  proteasome-mediated  degradation.  This  process 
unmasks the nuclear localization sequences of NF-B, which then accumulates in the nucleus, binds to 
B regulatory elements and activates target genes [15,16]. Chemopreventive phytochemicals, such as 
curcumin and capsaicin, are known to block the NF-B activation process [5–7]. 
Wnts are an evolutionarily conserved family of growth factors that are essential for a wide array of 
developmental  and  physiological  processes  [17,18].  The  activity  of  the  Wnt/-catenin  signaling 
pathway is dependent upon the amount of -catenin in the cytoplasm. In the absence of Wnt ligands, 
the  cytoplasmic  -catenin  level  is  kept  low  through  continuous  ubiquitin-proteasome-mediated 
degradation,  by  a  multiprotein  destruction  complex  containing  axin,  adenomatous  polyposis  coli 
(APC),  and  glycogen  synthase  kinase  3  (GSK3).  Upon  binding  of  Wnts  to  the  receptor  complex 
Frizzled  (Fz)  and  LDL  receptor-related  proteins  (LRP),  a  signal  is  transduced  to  activate  the 
cytoplasmic  phosphoprotein  Dishevelled  (Dvl).  Activated  Dvl  inhibits  GSK3,  thus  preventing 
phosphorylation of -catenin. Consequently, -catenin escapes proteasomal degradation, accumulates 
in the cytoplasm and subsequently translocates to the nucleus. In the nucleus, -catenin activates target 
genes in cooperation with transcription factors T-cell factor (TCF) and lymphoids enhancer factor 
(LEF)  [17,18].  Cyclin  D1  and  c-Myc,  cell  proliferation  and  apoptosis  regulators,  are  well  known 
targets  of  Wnt/-catenin  signaling  [17,18].  Mutation  of  the  APC  gene  occurs  in  the  majority  of 
sporadic  colorectal  cancers,  as  well  as  familial  adenomatous  polyposis  [17,18].  Chemopreventive 
phytochemicals,  such  as  curcumin  and  (-)-epigallocatechin  gallate,  are  known  to  block  the  
Wnt/-catenin  signaling  pathway  [19–22].  Therefore,  NF-B  and  Wnt  signaling  pathways  are 
important molecular targets of cancer prevention by natural compounds. 
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2.3. Overcoming multidrug resistance 
Cancer  chemotherapy  is  usually  a  marginal  proposition  in  the  sense  that  the  maximum  dose 
tolerated  by  the  patient  is  often  barely  sufficient  to  kill  a  useful  percentage  of  the  cancer  cells. 
Relatively small increases in drug resistance in cancer cells are thus sufficient to render the drug 
ineffective.  ABC  transporters  are  expressed  at  cancer  cell  membranes  and  can  cause  multidrug 
resistance [2–4]. Therefore, ABC transporters seem to be good targets for circumventing multidrug 
resistance. Since the discovery of P-glycoprotein in the 1970s, various attempts and clinical trials have 
been  carried  out  using  a  P-glycoprotein  inhibitor  such  as  verapamil  or  cyclosporine  to  overcome 
multidrug  resistance.  However,  due  to  the  side  effects  or  ineffectiveness  of  these  compounds,  a 
successful outcome has not been achieved [2–4]. In general, natural dietary phytochemicals from foods, 
herbs, and dietary supplements are thought to be less toxic to the body than medical drugs. The quest 
for  inhibitors  of  anticancer  drug  exporters  has  uncovered  natural  compounds  including  quercetin,  
(-)-epigallocatechin gallate, curcumin, capsaicin, and [6]-gingerol, as promising candidates [8–11]. 
Figure 1 shows the chemical structures and source of dietary chemopreventive phytochemicals that can 
inhibit P-glycoprotein. Cancer chemopreventive and chemosensitizing properties of several natural 
products are described in greater detail in the following sections. 
3. P-glycoprotein and Chemopreventive Phytochemicals 
3.1. Tea 
Tea (Camellia sinensis) consumption has been shown to reduce the risk of tumor formation at 
different organ sites including the skin, oral cavity, esophagus, stomach, intestine, lung, liver, pancreas, 
mammary gland, urinary bladder, and prostate [5–7]. (-)-Epigallocatechin gallate (EGCG), a major 
water-extractable constituent of tea, has been presumed to be the active compound for the cancer 
preventive effects. A cup of green tea (2.5 g of dried green tea leaves brewed in 200 mL of water) may 
contain 90 mg of EGCG, and similar or a slightly smaller amount of (-)-epigallocatechin, about 20 mg 
each of (-)-epicatechin gallate and (-)-epicatechin [23]. 
Nomura et al. [24] reported the inhibitory activity of EGCG on NF-B pathway in mouse epidermal 
cells.  In  the  JB6  mouse  epidermal  cells,  a  tumor  promoter  12-O-tetradecanoylphorbol-13-acetate 
(TPA)  markedly  induced  NF-B  activation.  EGCG  blocked  TPA-induced  phosphorylation  of  IB 
resulted in the inhibition of NF-B activity [24]. It was also reported that EGCG inhibits ultraviolet 
(UV)-induced phosphorylation of IB and activation of NF-B in human epidermal keratinocytes [25]. 
Dashwood and colleagues have reported the inhibition of heterocyclic amine 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine  (PhIP)-induced  formation  of  intestinal  polyps  in  Apc
min  mouse  by  
tea [26]. They subsequently revealed the inhibition of Wnt/-catenin signaling by tea constituents 
using  -catenin/TCF reporter construct  [21].  -Catenin/TCF reporter  activity in human embryonic 
kidney  293  (HEK293)  cells  was  inhibited  by  25  M  EGCG  [20].  Kim  et  al.  [22]  reported  the 
inhibition of Wnt/-catenin signaling by EGCG in human invasive breast cancer cells. EGCG induced 
the HBP1 transcriptional repressor, a suppressor of Wnt signaling, thus reducing both tumorigenic 
proliferation and invasiveness of breast cancer cells [22]. 
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Figure 1. Chemical structures and source of chemopreventive phytochemicals. 
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In addition to the anti -carcinogenic effects of EGCG, we  have revealed the inhibitory effects of 
EGCG and other tea catechins on the function of P -glycoprotein using human carcinoma KB-C2 cells 
and  fluorescent P -glycoprotein substrates  daunorubicin  and  rhodamine 123 [10]. KB -C2 is  a 
multidrug-resistant human epidermal carcinoma cell line that over -expresses P-glycoprotein [27,28]. 
Daunorubicin and rhodamine 123 have often been used in studies of P-glycoprotein-mediated transport. Toxins 2010, 2    
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Daunorubicin is also reported to be a substrate of multidrug resistance protein 1 (MRP1). However, 
MRP1 is scarcely found in KB-C2 cells, and its involvement in daunorubicin accumulation in KB-C2 
cells is negligible. We showed that tea catechins (10–100 M) increased the cellular accumulation of 
daunorubicin and rhodamine 123 in the order of (-)-epigallocatechin < (-)-epicatechin gallate < EGCG 
[10]. (-)-Epicatechin had no effects up to 300 M. We also measured the partition coefficients Poct of 
tea catechins between n-octanol and phosphate-buffered saline (PBS). The Poct values increased in the 
order  of  (-)-epigallocatechin  <  (-)-epicatechin  <  EGCG,  (-)-epicatechin  gallate  [10].  Therefore,  a 
correlation between partition coefficient and inhibitory effect on P-glycoprotein was not observed. The 
n-octanol/PBS partition coefficient of quercetin, a tea flavonoid, was larger than that of EGCG, but the 
inhibitory effect on P-glycoprotein of quercetin was smaller than that of EGCG [10]. Therefore, EGCG 
is  relatively  hydrophilic,  however  its  amphiphilic  chemical  structure  may  be  favorable  for  the 
interaction with either the substrate binding sites or the activity-modulating sites of P-glycoprotein. 
3.2. Turmeric 
Curcumin  is  a  major  component  of  the  culinary  spice  turmeric  (Curcuma  longa)  and  it  gives 
specific flavor and a yellow color to curry. Curcumin has strong anti-oxidant and anti-inflammatory 
properties and is reported to prevent the initiation, promotion, or progression of cancer. Curcumin is 
one of the most extensively investigated chemopreventive phytochemicals [29]. It is also reported that 
curcumin is pharmacologically safe. Human clinical trials indicated no dose-limiting toxicity when 
administered at doses of up to 10 g/day [29]. 
Curcumin is reported to suppress NF-B activation induced by TNF, phorbor esters, and hydrogen 
peroxide through suppression of IB degradation [6,7,29]. In 1995, Singh and Aggarwal [30] firstly 
reported that curcumin is a potent inhibitor of NF-B signaling. They used human myelomonoblastic 
leukemia cell line ML-1a and electrophoretic mobility shift assay (EMSA) to show the activation of 
NF-B in ML-1a cells by TNF, TPA and hydrogen peroxide [30]. Curcumin blocked the TNF-induced 
phosphorylation and degradation of IB, and translocation of NF-B to the nucleus [30]. The activation 
of NF-B by TNF, TPA and hydrogen peroxide were inhibited by curcumin [30]. Chun et al. [31] also 
reported  that  curcumin  inhibits  the  TPA-induced  expression  of  cyclooxygenase-2  in  mouse  skin 
through the suppression of NF-B activation. 
The Wnt signaling pathway is also an important target of the cancer preventive activity of curcumin.  
Jaiswal et al. [19] showed that -catenin-induced c-Myc expression is important in curcumin-induced 
growth arrest and apoptosis in human colon cancer HCT-116 cells. Park et al. [20] have reported the 
inhibitory mechanism of curcumin using -catenin/TCF reporter construct. They suggested that the 
inhibitory mechanism of curcumin is related to the reduced amount of nuclear -catenin and TCF-4 
proteins [20]. 
The  mammalian  target  of  rapamycin  (mTOR),  a  serine/threonine  kinase,  is  downstream  in  the 
phosphatidylinositol  3-kinase  (PI3K)/Akt  (protein  kinase  B)  cascade.  mTOR  integrates  signals 
regarding nutrient and energy availability, mitogen activation, and thus regulates the cell growth and 
survival [32]. Recent findings show that curcumin can inhibit mTOR signaling in cancer cells [33,34]. 
Yu et al. [34] have reported curcumin inhibits mTOR signaling in human prostate cancer PC-3 cells 
through a protein phosphatase-dependent dephosphorylation mechanism. Toxins 2010, 2    
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We  have  examined  the  inhibitory  effect  of  curcumin  on  human  P-glycoprotein  using  
P-glycoprotein-overexpressing  human  carcinoma  KB-C2  cells  and  fluorescent  P-glycoprotein 
substrates  [11].  Curcumin  increased  the  accumulation  of  daunorubicin  in  KB-C2  cells  in  a 
concentration-dependent manner. The cellular accumulation of rhodamine 123 was also increased in 
the presence of curcumin. Since curcumin inhibits the efflux of P-glycoprotein substrates, the elevation 
of substrate accumulation seems to be induced by the inhibition of the efflux transporter. The efflux of 
rhodamine 123 from KB-C2 cells was decreased by curcumin [11]. Taken together, these findings 
indicate  that  curcumin  has  an  inhibitory  effect  on  P-glycoprotein  function,  and  may  have 
chemosensitizing potency, in addition to its own chemopreventive properties. 
3.3. Chili pepper and ginger 
Capsaicin is a pungent component of hot and red chili pepper (Capsicum annuum). In addition to 
alleviating pain and itching in humans, capsaicin has exhibited chemopreventive effects, suppressing 
carcinogenesis of the skin, colon, lung, tongue, and prostate [6,7]. Singh et al. [35] have reported the 
inhibition of TNF-induced NF-B activation in human myeloid ML-1a cells by capsaicin. Capsaicin 
blocked the degradation of IB, and nuclear translocation of NF-B [35]. Han et al. [36] also showed 
that capsaicin inhibits the TPA-induced activation of NF-B in mouse skin. 
[6]-Gingerol is a phenolic substance responsible for the spicy taste of ginger (Zingiber officinale). 
[6]-Gingerol has also been linked with prevention of cancer. It has been reported that [6]-gingerol 
inhibits the proliferation of cancer cells including prostate, gastric, and breast [6,7]. Kim et al. [37] 
reported that [6]-gingerol suppresses TPA-induced degradation of IB and translocation of NF-B to 
the  nucleus,  consequently  inhibits  the  activation  of  NF-B.  Lee  et  al.  [38]  recently  reported  that  
[6]-gingerol downregulates -catenin-depenent cyclin D1 levels and induce apoptosis in human colon 
cancer cells. 
Capsaicin and [6]-gingerol have also shown to have inhibitory effects on human P-glycoprotein [11]. 
Capsaicin and [6]-gingerol increased the intracellular concentration of P-glycoprotein substrates by 
inhibiting  this  anticancer  drug  efflux  transporter  [11].  In  the  presence  of  50  M  capsaicin  or  
[6]-gingerol, multidrug-resistant carcinoma KB-C2 cells were more susceptible to the cytotoxicity of 
vinblastine, a P-glycoprotein substrate, as compared with vinblastine alone [11]. This demonstrates 
that  capsaicin  and  [6]-gingerol  can  partially  reverse  multidrug  resistance  in  cells  that  express  
P-glycoprotein. 
3.4. Rosemary 
The leaves of rosemary (Rosmarinus officinalis) are commonly used as a spice in cooking. However, 
because  of  the  presence  of  phenolic  diterpenes  and  triterpenes  with  strong  antioxidative  activity, 
interest has grown in using rosemary as a natural antioxidant in foods [39–46]. Extract of rosemary 
leaves have been used to prevent lipid autooxidation and to inhibit the oxidation of edible oils or fats. 
The antioxidative activity of rosemary extract is comparable with that of known antioxidants, such as 
butylated  hydroxytoluene  (BHT)  and  butylated  hydroxyanisole  (BHA),  without  the  cytotoxic  and 
carcinogenic risk. Among the constituents of rosemary extracts, 90% of the total antioxidative activity 
was derived from carnosic acid and carnosol [39–44]. Rosemary also yields substantial quantities of Toxins 2010, 2    
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the polyphenolic antioxidant rosmarinic acid. Rosemary extract is regarded as safe, and a relatively 
high concentration, 0.02 to 0.05% (w/w), is used for food production [45,46]. A typical commercial 
rosemary extract contains 20% (w/w) carnosic acid. Therefore, 100 g of meat could contain 30 mol of 
carnosic acid [46]. 
In addition to antioxidative activities, rosemary phytochemicals are reported to have antimicrobial, 
anti-inflammatory, and anticancer properties [47–51]. Topical application of carnosol and ursolic acid 
to  mouse  skin  inhibited  TPA-induced  inflammation  and  tumorigenesis  [47]. Carnosol restricts  the 
invasion  of  B16/F10  mouse  melanoma  cells  by  reducing  metalloproteinase-9  activity  through 
inhibition  of  NF-B  [50].  Carnosol  is  shown  to  block  the  lipopolysaccharide  (LPS)-induced 
phosphorylation and degradation of IB, and nuclear translocation of NF-B [48]. Ursolic acid inhibits 
NF-B  activation  induced  by  various  carcinogens  [49].  Carnosol  is  also  reported  to  prevent  
-catenin/APC-associated  intestinal  carcinogenesis  [51].  Therefore,  rosemary  phytochemicals, 
carnosic acid, carnosol, rosmarinic acid, and ursolic acid, are regarded as strong natural antioxidants 
and promising dietary chemopreventive agents. 
We  have  examined  the  effects  of  rosemary  phytochemicals  on  the  function  of  human  
P-glycoprotein [52]. Carnosic acid, carnosol, and ursolic acid increased the cellular accumulation of 
daunorubicin or rhodamine 123 in multidrug-resistant KB-C2 cells. On the other hand, rosmarinic acid 
had no effect on the accumulation of daunorubicin [52]. We have previously investigated the effects of 
flavonoids on P-glycoprotein function [53]. The inhibitory effects of flavonoids were in the order of 
kaempferol > quercetin, baicalein > myricetin > fisetin, morin. Quercetin-3-glycoside and rutin had no 
effects [53]. These results indicate that the hydrophobicity of phytochemicals is important for their 
inhibitory  effects  on  the  efflux  of  substrates  by  P-glycoprotein.  Rosmarinic  acid,  a  hydrophilic 
antioxidant, had no effect on P-glycoprotein [52]. In contrast, ursolic acid, a steroid-like triterpene that 
has  little  or  no  antioxidative  activity,  inhibited  P-glycoprotein  function  [52].  Therefore,  the 
hydrophobicity,  not  the  antioxidative  activity,  of  phytochemicals  could  be  important  for  their 
inhibitory  effects  on  P-glycoprotein  activity.  We  have  also  examined  the  effects  of  rosemary 
phytochemical on the resistance  to  vinblastine cytotoxicity. In the presence of as little as 10 M 
concentration of carnosic acid, KB-C2 cells were more susceptible to the cytotoxicity of vinblastine, a 
P-glycoprotein substrate, as compared with vinblastine alone [52]. This demonstrates that rosemary 
phytochemical  carnosic  acid  has  a  chemosensitizing  effect,  reversing  P-glycoprotein-mediated 
multidrug resistance by increasing the intracellular accumulation of anticancer drug. 
3.5. Citrus fruits 
The ingestion of citrus fruit has been reported to be beneficial for the reduction of certain types of 
human cancer. Citrus phytochemicals, including monoterpenes, limonoids, flavonoids, and coumarins 
are  demonstrated  to  have  anti-carcinogenic  effects  [54].  Auraptene  (7-geranyloxycoumarin),  a 
coumarin-related  compound  occurring  widely  in  citrus  fruit  (e.g.,  grapefruit),  markedly  inhibited  
4-nitroquinoline  1-oxide-induced  oral  carcinogenesis  in  rats  and  suppressed  the  growth  of  human 
prostate  carcinoma  cells  [55–57].  Auraptene  also  showed  suppression  of  TPA-  and  LPS-  induced 
inflammatory responses [58]. Nobiletin (5,6,7,8,3',4'-hexamethoxyflavone), a polymethoxyflavonoid in 
citrus fruit (e.g., mandarins and oranges), is an inhibitor of the generation of both NO and O2
- in Toxins 2010, 2    
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leukocytes and showed strong inhibitory effects on TPA-induced skin inflammation, oxidative stress, 
and tumor promotion in mice and the growth of human prostate carcinoma cells [57,59]. Therefore, 
citrus phytochemicals, auraptene and nobiletin, are considered promising chemopreventive agents. 
The concentration of auraptene is 6.03 M in grapefruit juice, and the concentration of nobiletin is 
6.71 to 11.43 M in Valencia orange juice [55,60–62]. It is reported that these concentrations could be 
sufficient to inhibit the function of P-glycoprotein [63]. However, further studies of the absorption, 
distribution, metabolism, and excretion of citrus phytochemicals in the human body are needed to 
clarify the inhibitory effects of these compounds at the site of drug action, in the tumor tissues and 
cancer cells. 
It is reported that ATP hydrolysis and substrate transport are tightly coupled, and most compounds 
that are known to be transported by the ABC transporter stimulate ATPase activity [2]. To explore the 
inhibitory mechanism of citrus phytochemicals on the function of P-glycoprotein, effects on ATPase 
activity of P-glycoprotein was measured using human P-glycoprotein membranes from baculovirus 
infected insect cells. The ATPase activity of P-glycoprotein was stimulated by verapamil, a known 
substrate  of  P-glycoprotein  [63].  Auraptene  or  nobiletin  alone  also  stimulated  the  basal  ATPase 
activity of P-glycoprotein [63]. Auraptene and nobiletin further enhanced the verapamil-stimulated 
ATPase activity of P-glycoprotein [63]. These results suggest that auraptene and nobiletin could be 
substrates of P-glycoprotein, and competitively interact at drug-binding site of P-glycoprotein. 
3.6. Plant sterols 
Cholesterol  is  an  essential  structural  component  of  animal  cell  membranes.  Plant  sterols  play 
analogues roles in plants. The major dietary phytosterols are -sitosterol, campesterol and stigmasterol, 
and their contents are higher in edible oils, seeds and nuts. Dietary plant sterols and stanols have been 
recognized as efficient modulators of plasma low-density lipoprotein (LDL) cholesterols in humans for 
decades [64,65]. The mechanism underlying this hypocholesterolemic effect is a reduction in cholesterol 
absorption from the intestinal lumen into the circulation. Elevated levels of serum LDL cholesterol is a 
major cause of cardiovascular disease, and several studies showed that phytosterols reduce coronary 
heart disease risk [64,65]. Epidemiologic and experimental studies also suggest the role of dietary 
plant sterols in the protection from cancers, such as colon, breast and prostate cancers [66]. 
Resin of the gum of the guggul tree (Commiphora mukul) has been used to treat hyperlipidemia, 
obesity, arthritis, and inflammation in humans [67,68]. The active substance from the resin has been 
demonstrated to be the plant sterol guggulsterone [67,68]. Guggulipid is an extract of the resin, which 
is enriched for guggulsterone. Several clinical trials demonstrate that guggulipid effectively lowers 
serum LDL cholesterols levels, although these data have been recently questioned [67–69]. Guggulipid 
is  commonly  used  in  India  for  treatment  of  hyperlipidemia  and  obesity  and  is  widely  available 
worldwide as an herbal dietary supplement. The pharmacological activity of guggulsterone has been 
suggested  to  be  mediated  by  the  antagonism  of  the  nuclear  receptor,  farnesoid  X  receptor  (FXR, 
NR1H4) [70,71]. Guggulsterone also suppresses TNF-induced phosphorylation, degradation of IB 
and translocation of NF-B to the nucleus [72]. Consequently, guggulsterone inhibits the activation of 
NF-B and expression of anti-apoptotic gene products, and thus enhance apoptosis in human lung 
carcinoma cells [72]. Toxins 2010, 2    
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We  have  investigated  the  effects  of  plant  sterols  on  P-glycoprotein  function  [73].  -Sitosterol, 
campesterol, stigmasterol, -sitostanol, -cholestanol and fucosterol had no effects [73]. These results 
suggest  that  commonly  consumed  dietary  plant  sterols,  such  as  -sitosterol,  campesterol  and 
stigmasterol,  do  not  interact  with  human  P-glycoprotein.  In  contrast,  guggulsterone  increased  the 
cellular  accumulation  of  daunorubicin  in  P-glycoprotein-overexpressing  KB-C2  cells  in  a 
concentration-dependent  manner  [73].  Since  this  phytosterol  does  not  show  any  effect  in  
P-glycoprotein-lacking KB-3-1 cells, the elevation of substrate accumulation in KB-C2 cells seems to 
be induced by the inhibition of the anticancer drug efflux transporter. The cellular accumulation of 
rhodamine 123 was increased, and the efflux of rhodamine 123 from KB-C2 cells was decreased by 
guggulsterone [73]. Guggulsterone also stimulated the ATPase activity of P-glycoprotein. Therefore, 
guggulsterone could be a substrate of P-glycoprotein, and competitively inhibit P-glycoprotein at its 
drug-binding site. 
3.7. Others 
In  addition to the above-mentioned phytochemicals, various natural compounds are reported to 
possess cancer preventive properties [5–7]. Several phytochemicals were also studied for their effect 
on P-glycoprotein [11,74,75]. Resveratrol, a phytoalexin present in grapes (Vitis vinifera), sesamin, a 
lignan existing exclusively and abundantly in sesame (Sesamum indicum) seeds, matairesinol found in 
soybean (Glycine max), glycyrrhetinic acid and glabridin in licorice (Glycyrrhiza glabra) extract, and 
ginsenosides and their hydrolyzed metabolites from the root of Panax ginseng have been shown for 
their inhibitory effects on the human P-glycoprotein [11,74,75]. 
4. MRP1 and Chemopreventive Phytochemicals 
Multidrug resistance protein 1 (MRP1, ABCC1), encoded by the ABCC1 gene, belongs to the ABC 
transporter family, and is the second member to be identified. MRP1 consists of 17 transmembrane 
domains  and  two  ATP-binding  sites,  and  acts  as  a  drug  efflux  transporter  [3,4].  In  contrast  to  
P-glycoprotein, MRP1 expression is widespread in the body, including lung, testis, skeletal and cardiac 
muscles [3,4]. P-glycoprotein and MRP1 also differ in substrate specificity. Although the mechanisms 
by  which  substrates  are  recognized  by  P-glycoprotein  and  MRP1  have  not  been  fully  clarified,  
P-glycoprotein seems to prefer amphipathic cationic compounds, and MRP1, anionic compounds [3,4]. 
Both  P-glycoprotein  and  MRP1  act  as  anticancer  drug  efflux  transporters  and  cause  multidrug 
resistance. It is also reported that P-glycoprotein and MRP1 were major determinants of innate drug 
sensitivity,  even  when  the  level  of  expression  was  low  in  drug-naï ve  tumors  [76].  Inhibitors  of  
P-glycoprotein and MRP1 are useful not only to reverse or prevent acquired drug resistance, but also 
to sensitize drug-naï ve untreated tumors to anticancer drugs. Therefore, MRP1 is also a promising 
target for the reversal of multidrug resistance and a better outcome of cancer chemotherapy. 
Several natural compounds were investigated for their inhibitory effects on MRP1 [52,63,73,74,77–81]. 
Quercetin,  EGCG  and  curcumin  are  reported  to  interact  with  human  MRP1  [77–81].  We  have 
investigated the effects of chemopreventive phytochemicals on the function of MRP1 using human 
MRP1 gene-transfected KB/MRP cells [52,63,73,74]. None of the rosemary phytochemicals, carnosic 
acid, carnosol, rosmarinic acid, and ursolic acid, affects the MRP1 activity [52]. Citrus phytochemical Toxins 2010, 2    
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nobiletin, but not auraptene, inhibits the function of MRP1 [63]. Dietary plant sterols -sitosterol, 
campesterol, stigmasterol, -sitostanol, -cholestanol and fucosterol had no effects on MRP1 [73]. 
Guggulsterone is an inhibitor of both P-glycoprotein and MRP1 [73]. 
Glycyrrhetinic acid is also a dual inhibitor of P-glycoprotein and MRP1 [74]. It is interesting that 
the  inhibitory  mechanisms  of  glycyrrhetinic  acid might be  different in  the two ABC transporters. 
Glycyrrhetinic  acid  alone  stimulated the basal  ATPase activity  of MRP1 [74]. In  the presence  of  
NEM-GS, an MRP1 substrate, the ATP hydrolysis by MRP1 was further stimulated by glycyrrhetinic 
acid. In contrast to the result of MRP1 ATPase activity, glycyrrhetinic acid alone had no effect on the 
ATPase activity of P-glycoprotein. However, glycyrrhetinic acid inhibited the verapamil-stimulated  
P-glycoprotein ATPase activity [74]. These results suggest that glycyrrhetinic acid could be a substrate 
of MRP1, and competitively interact at drug-binding site of MRP1. In contrast, glycyrrhetinic acid is 
not a substrate of P-glycoprotein, but possibly interacts noncompetitively at ATP hydrolytic site of  
P-glycoprotein. In the presence of 100 M concentration of glycyrrhetinic acid, KB-C2 and KB/MRP 
cells  were  more  susceptible  to  the  cytotoxicity  of  vinblastine,  a  P-glycoprotein  substrate,  or 
doxorubicin,  an  MRP1  substrate,  as  compared  with  vinblastine  or  doxorubicin  alone  [74].  This 
demonstrates  that  glycyrrhetinic  acid  has  a  chemosensitizing  effect,  reversing  P-glycoprotein  and 
MRP1-mediated multidrug resistance by increasing the intracellular accumulation of anticancer drug. 
5. Future Perspective 
Although P-glycoprotein and MRP1 are key determinants of drug sensitivity, other anticancer drug 
efflux transporters, such as breast cancer resistance protein (BCRP, ABCG2), can cause multidrug 
resistance  [3,4].  At  present,  interactions  between  natural  compounds  and  anticancer  drug  efflux 
transporters, other than P-glycoprotein and MRP1, have not been well investigated. Therefore, it is 
important to study the inhibitory effects of phytochemicals on BCRP and other ABC transporters. 
In the studies using cancer cell lines, relatively higher doses of phytochemicals are often used. Even 
though the natural compounds are regarded as safe, a low amount is favorable for future in vivo studies. 
It is noteworthy to consider that the level of P-glycoprotein expression in the cell line is much greater 
than that in human tissues [2–4]. Thus, lower concentrations of phytochemicals would be effective in 
modulating  in  vivo  P-glycoprotein  activities.  In  addition,  synergistic  effects  with  other  dietary 
phytochemicals on ABC transporter function should be considered. Combinatorial therapy with several 
natural  compounds  and  conventional  anticancer  drugs  must  be  developed  for  the  future  cancer 
chemotherapy. 
As described in this review, cellular signaling pathways, such as NF-B and Wnt, are important 
molecular  targets  of  cancer  prevention  by  natural  compounds.  Recent  studies  have  revealed  that  
P-glycoprotein is also regulated by these pathways [82]. -Catenin/TCF binding sites in the MDR1 
promoter  were  described  previously  and  recently  it  has  been  shown  that  the  activation  of  
Wnt/-catenin  signaling  increases  P-glycoprotein  expression  [83–86].  In  contrast,  suppression  of 
Wnt/-catenin signaling decreased P-glycoprotein expression [85,86]. Natural compounds that inhibit 
both of P-glycoprotein function and expression can be useful for overcoming multidrug resistance in 
human cancer. Therefore, I am now trying to find such compounds by using both P-glycoprotein-
lacking anticancer drug sensitive cells and P-glycoprotein-overexpressing multidrug-resistant cells. Toxins 2010, 2    
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It is also very important to investigate the absorption, distribution, metabolism, and excretion of 
chemopreventive phytochemicals in the human body, to clarify the interaction with anticancer drugs at 
the site of drug action, in the tumor tissues and cancer cells. 
6. Conclusion 
In addition to the beneficial effects of natural compounds, the inhibitory effects of phytochemicals 
on the anticancer drug efflux transporter P-glycoprotein and MRP1 have been revealed, which can 
reverse  the  multidrug  resistance.  Therefore,  dietary  chemopreventive  phytochemicals,  such  as 
nobiletin, guggulsterone and glycyrrhetinic acid, can be considered promising lead compounds for the 
design  of  more  efficacious  and  less  toxic  chemosensitizing  agents  to  enhance  the  efficacy  of 
chemotherapy in cancer patients. 
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